MDNA Medicenna Therapeutics Corporation

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of January 2024

 

Commission File Number:  001-39458

 

Medicenna Therapeutics Corp.

(Translation of registrant’s name into English)

 

2 Bloor St. W. 7^th Floor

Toronto, Ontario M4W 3E2

Canada

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

x      Form 20-F

¨     Form 40-F

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Medicenna Therapeutics Corp.
	(Registrant)
Date: January 5, 2024	By:	/s/ Fahar Merchant
		Name:	Fahar Merchant, PhD
		Title:	Chief Executive Officer

 

 

Form 6-K Exhibit Index

 

Exhibit Number		Document Description
99.1		Notice of Change of Auditor
99.2		Letter from Predecessor Auditor

 

 

 

Exhibit 99.1

 

MEDICENNA THERAPEUTICS CORP.

(the “Corporation”)

 

NOTICE OF CHANGE OF AUDITOR

 

TO:	Alberta Securities Commission
	British Columbia Securities Commission
	Ontario Securities Commission

 

AND TO:

PricewaterhouseCoopers LLP (“PwC”)

 

Pursuant to National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”), the Corporation hereby gives notice as follows:

 

1.             On December 20, 2023, PwC resigned as auditor of the Corporation.

 

2.             There were no reservations or modified opinions contained in PwC’s report on the financial statements of the Corporation or its predecessor for the financial years ended March 31, 2023 or March 31, 2022.

 

3.             In the opinion of the board of directors of the Corporation (the “Board”), there have been no “reportable events” as such term is defined in NI 51-102, between the Corporation and PwC.

 

4.             Following the resignation of PwC, the contents and filing of this notice have been recommended by the audit committee of the Corporation and approved by the Board.

 

Dated this 20^th day of December, 2023.

 

MEDICENNA THERAPEUTICS CORP.

 

Per:	(s) Fahar Merchant
	Name:	Fahar Merchant
	Title:	President and Chief Executive Officer

 

 

 

Exhibit 99.2

 

 

December 20, 2023

 

To:	Alberta Securities Commission
	British Columbia Securities Commission
	Ontario Securities Commission

 

We have read the statements made by Medicenna Therapeutics Corp. in the attached copy of change of auditor notice dated December 20, 2023, which we understand will be filed pursuant to Section 4.11 of National Instrument 51-102.

 

We agree with the statements in the change of auditor notice dated December 20, 2023.

 

Yours very truly,

 

 

Chartered Professional Accountants

 

PricewaterhouseCoopers LLP

PwC Centre, 354 Davis Road, Suite 600, Oakville, Ontario, Canada L6J 0C5

T: +1 905 815 6300, F: +1 905 815 6499, ca_oakville_main_fax@pwc.com, www.pwc.com/ca

 

“PwC” refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership.

 

---